TRVI (Trevi Therapeutics) EBIT per Share : $-0.47 (TTM As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Trevi Therapeutics EBIT per Share?

Trevi Therapeutics's EBIT per Share for the three months ended in Dec. 2024 was $-0.11. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $-0.47.

During the past 3 years, the average EBIT per Share Growth Rate was 29.20% per year. During the past 5 years, the average EBIT per Share Growth Rate was 32.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Trevi Therapeutics's EBIT per Share or its related term are showing as below:

TRVI' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -25.1 Med: 29.2 Max: 42.4
Current: 29.2

During the past 8 years, the highest 3-Year average EBIT per Share Growth Rate of Trevi Therapeutics was 42.40% per year. The lowest was -25.10% per year. And the median was 29.20% per year.

TRVI's 3-Year EBIT Growth Rate is ranked better than
74.53% of 1233 companies
in the Biotechnology industry
Industry Median: 8 vs TRVI: 29.20

Trevi Therapeutics's EBIT for the three months ended in Dec. 2024 was $-11.40 Mil.

Trevi Therapeutics EBIT per Share Historical Data

The historical data trend for Trevi Therapeutics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Trevi Therapeutics EBIT per Share Chart

Trevi Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EBIT per Share

Get a 7-Day Free Trial

-1.79

-1.43

-0.43

-0.29

-0.47

Trevi Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
EBIT per Share	Get a 7-Day Free Trial															-0.08	-0.11	-0.12	-0.13	-0.11

Trevi Therapeutics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Trevi Therapeutics's EBIT per Share for the fiscal year that ended in Dec. 2024 is calculated as

	EBIT per Share		(A: Dec. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-47.937	/	101.972
=	-0.47

Trevi Therapeutics's EBIT per Share for the quarter that ended in Dec. 2024 is calculated as

	EBIT per Share		(Q: Dec. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-11.398	/	106.039
=	-0.11

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.47

Trevi Therapeutics (NAS:TRVI) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Trevi Therapeutics EBIT per Share Related Terms

Thank you for viewing the detailed overview of Trevi Therapeutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Trevi Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Trevi Therapeutics Inc (NAS:TRVI) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

195 Church Street, 16th Floor, New Haven, CT, USA, 06510

Website

https://www.trevitherapeutics.com

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.

Executives

Thomas Sciascia	10 percent owner, officer: Chief Medical Officer	39 OLD RIDGEBURY RD. SUITE 11, DANBURY CT 06810
Jennifer L Good	director, 10 percent owner, officer: See Remarks	15 GREAT RING ROAD, SANDY HOOK CT 06482
Farrell Simon	officer: Chief Commercial Officer	C/O TREVI THERAPEUTICS, INC., 195 CHURCH STREET, FLOOR 14, NEW HAVEN CT 06510
David P Meeker	director, 10 percent owner	C/O PENWEST PHARMACEUTICALS CO, 39 OLD RIDGEBURY ROAD SUITE 11, DANBURY CT 06810
Lisa Delfini	officer: Chief Financial Officer	C/O TREVI THERAPEUTICS, INC., 195 CHURCH STREET, FL. 14, NEW HAVEN CT 06510
David J Clark	officer: Chief Medical Officer	131 HARTWELL AVE, LEXINGTON MA 02421
Tpg Gp A, Llc	10 percent owner	301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102
Scott D Sandell	10 percent owner
Forest Baskett	10 percent owner
Peter W. Sonsini	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
Florence Anthony A. Jr.	10 percent owner	5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815
Ali Behbahani	10 percent owner	5425 WISCONSIN AVE, CHEVY CHASE MD 20815
Carmen Chang	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
New Enterprise Associates 16, L.p.	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Mohamad Makhzoumi	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025